| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698426 | Clinical Oncology | 2013 | 6 Pages |
Abstract
The incidence of mesothelioma is increasing. Adverse prognostic factors include non-epithelioid histology, performance status and hypoalbuminaemia. Overall survival has not improved significantly, but treatment with carboplatin/pemetrexed chemotherapy is associated with a significant survival benefit.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Murphy, G. Probert, J. Anderson, S. Pollock, I. Taylor, H. Clague, K. Sridharan,